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Hayley Dickinson1, Stacey Ellery1, Zoe Ireland2, Domenic LaRosa1, Rodney Snow3 and David W Walker1,4*Abstract
While the use of creatine in human pregnancy is yet to be fully evaluated, its long-term use in healthy adults
appears to be safe, and its well documented neuroprotective properties have recently been extended by
demonstrations that creatine improves cognitive function in normal and elderly people, and motor skills in
sleep-deprived subjects. Creatine has many actions likely to benefit the fetus and newborn, because pregnancy is a
state of heightened metabolic activity, and the placenta is a key source of free radicals of oxygen and nitrogen. The
multiple benefits of supplementary creatine arise from the fact that the creatine-phosphocreatine [PCr] system has
physiologically important roles that include maintenance of intracellular ATP and acid–base balance, post-ischaemic
recovery of protein synthesis, cerebral vasodilation, antioxidant actions, and stabilisation of lipid membranes. In the
brain, creatine not only reduces lipid peroxidation and improves cerebral perfusion, its interaction with the
benzodiazepine site of the GABAA receptor is likely to counteract the effects of glutamate excitotoxicity – actions
that may protect the preterm and term fetal brain from the effects of birth hypoxia. In this review we discuss the
development of creatine synthesis during fetal life, the transfer of creatine from mother to fetus, and propose that
creatine supplementation during pregnancy may have benefits for the fetus and neonate whenever oxidative stress
or feto-placental hypoxia arise, as in cases of fetal growth restriction, premature birth, or when parturition is delayed
or complicated by oxygen deprivation of the newborn.Introduction
The need for a therapy that reduces the probability of
perinatal morbidity and mortality
Two areas in obstetric and neonatal medicine that lack ef-
fective prophylactic treatments are premature birth and
neonatal hypoxic-ischemic encephalopathy (HIE). It is well
known that morbidity and mortality are higher for babies
born pre-term [1]. Infants surviving premature birth can
be left with severe, life-long disabilities of the nervous sys-
tem such as cerebral palsy (CP), occurring not only as a* Correspondence: david.walker@monash.edu
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unless otherwise stated.result of the prematurity, but also from co-existing obstet-
ric problems such as intrauterine infection, chronic fetal
hypoxia, or with the problems that arise during resuscita-
tion of the infant [2,3].
Systematic reviews show that maternal administration
of corticosteroids for impending preterm birth signifi-
cantly reduce the risk of neonatal death, respiratory dis-
tress, cerebroventricular haemorrhage, and necrotising
enterocolitis, and clearly reduces the requirement for neo-
natal respiratory support and intensive care [4]. Antenatal
magnesium sulfate administration has also been shown to
reduce the risk of cerebral palsy when administered to
women immediately prior to preterm birth [5]. Maternal
administration of the xanthine oxidase inhibitor allopur-
inol is under trial as a means of protecting the fetal brainral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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treatments are given late, and only when preterm labour is
obvious and inevitable or the fetus is already clearly sub-
jected to severe hypoxia. These treatments require tertiary
level medical care, restricting their use to places with high
levels of obstetric surveillance. In the case of allopurinol,
significant concerns have been raised about its likely inter-
ference with normative and hypoxic regulation of the fetal
circulation [7]. Notwithstanding the use of antenatal
steroids and magnesium sulphate to lower the risk of
hypoxia-induced brain injury at birth (pre-term or
term), there are currently no accepted treatments that
are recommended for use during the 2nd and 3rd trimester
of pregnancy for the purpose of preventing birth-related
hypoxic-ischemic encephalopathy.
Most perinatal demise still occurs in 3rd world settings
[8]. The World Health Organization estimates that up to
9 million newborn babies suffer birth hypoxia each year,
leading to an estimated 1.2 million deaths (29% of global
neonatal deaths), and similar numbers of infants who de-
velop severe disability [8,9]. In addition to CP, cognitive
and behavioural dysfunctions and psychiatric illnesses
such as autism and schizophrenia are all disorders that
occur more often in infants born from pregnancies with a
history of obstetric complications, including prematurity,
fetal growth restriction, or birth hypoxia [10]. The great
challenge in developing an effective prophylactic treat-
ment for preterm birth, birth-related HIE – or instances
where these separate risks to the developing brain may
combine – remains the inherent difficulty of predicting
their occurrence [11]. Therefore, we need strategies that
prevent, rather than rescue perinatal brain injury.
The most successful and commonly used clinical
treatment for HIE is head cooling or total body cooling
[11-13], but limitations include the need to apply it
early after the onset of HIE. When applied in the 6 hATP
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ity, and it significantly reduces the incidence of moderate
to severe neurodevelopmental disability [13,14]. A recent
multi-centre review concluded that no additional adverse
effects or organ dysfunction arise from hypothermia treat-
ment, but adverse outcomes have been reported when
hypothermia is applied to healthy term infants [11]. Much
of the delay in applying this rescue treatment – and
therefore, in reducing its effectiveness - comes from the
time taken to assess the neonate as being ‘suitable for
treatment’.
Given the difficulty in: (i) the early prediction of pre-
term birth and perinatal hypoxia; (ii) the narrow thera-
peutic window for treatment: and (iii) the multi-organ
dysfunction that is often an outcome - it is evident that
the clinical practice of obstetrics still lacks effective
means to prevent the morbidity that remains associated
with preterm birth. Because neonatal hypothermia requires
specialised equipment and trained personnel to administer
it, its use and effectiveness in reducing the global burden
of birth hypoxia is likely to remain limited.
Review
Creatine as a therapy for the 3rd trimester
The synthesis of creatine and its availability in a diet
containing meat, milk products and fish is shown in
Figure 1. Human adults obtain approximately half of
their daily requirement for creatine from a diet contain-
ing meat, fish and other animal products, the remainder
being synthesized endogenously from arginine, glycine
and methionine in a two-step process involving arginine:
glycine aminotransferase (AGAT), principally in the kid-
ney, followed by hepatic methylation via guanidinoacetate
methyltransferase (GAMT). Creatine is then released from
the liver into the circulation and taken up by most tissues,
especially muscle, by means of the creatine transporterGAA
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ivity producing creatine. Once synthesized, creatine is released from
cle, by means of the creatine transporter. Inside the tissues a proportion
. One important aspect of creatine biosynthesis is that the daily utilization
of ‘labile’ methyl groups (methionine + choline) in an average diet. Thus,
ynthesis, responsible for half of our daily requirement for creatine, may be
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the creatine is phosphorylated to form phosphocreatine
via the action of creatine phosphokinase. Despite this
endogenous synthesis, ingesting creatine increases the
creatine content of skeletal muscle [15] and brain [16]
indicating that in healthy people the intracellular pool
of creatine is not fully saturated.
Creatine is an amino acid derivative involved with cellu-
lar energy production, but other beneficial effects of creat-
ine have been identified, including antioxidant actions,
stabilization of lipid membranes, and interactions with
glutamate and GABAA receptors that diminish excitotoxi-
city [17]. Recent animal experiments demonstrate that
when given as a supplement to the mother’s diet during
pregnancy, creatine protects the fetal brain, diaphragm,
and kidney against hypoxic insult at term [18-20]. Creatine
is not yet used in human pregnancy, but the positive re-
sults from these animal experiments suggest that creatine
supplementation in the 2nd or 3rd trimester of human
pregnancy could provide benefit to all pregnant women
against the risk of antenatally or perinatally acquired brain
injury, in much the same way that folate is now used to
prevent neural tube defects in early pregnancy.
Creatine therapy can also be distinguished from hypo-
thermia and magnesium sulphate in providing protection
to a number of major organs against the physiological
challenge of the transition from fetal to newborn life. We
propose that the ‘pleiotropic’ properties of creatine will
have benefits for many fetal tissues where vasoconstric-
tion, oxidative stress, or glutamate toxicity may arise, in
addition to its main function of maintaining mitochondrial
function and ATP turnover.
Pregnancy is a state of heightened metabolic activity
with extra nutritional requirements by the mother, and
even in healthy pregnancy there is increased generation
of oxygen and nitrogen free radicals [21], a key source of
which is the placenta [22]. Fetal tissues, and the develop-
ing brain in particular, are vulnerable to oxidative stress
especially if infection is present or inflammatory processes
are otherwise triggered. The idea that anti-oxidants may
protect the fetus against oxidative stress, especially in late
pregnancy, has recently been reviewed [23]. The possibility
that many problems in pregnancy arise from inadequate
nutrient supply to the fetus, usually discussed mainly in
relation to placenta transfer of glucose and essential amino
acids, is now readily accepted [24]. However, in these
cases, and especially in instances of fetal growth restric-
tion, the fetal acquisition of creatine has never been
examined.
A further reason for considering the use of creatine
supplementation in pregnancy arises from the possibility
that the preterm infant may become creatine depleted
because it has not yet developed full capacity to
synthesize creatine, or is unable to fully retain it by renalreabsorption. We must presume that the fetal source of
creatine is placental transfer of maternal creatine until
such time that the reno-hepatic capacity is sufficiently
developed, but just when this occurs in human preg-
nancy is not yet known. In a recent study of preterm
(32–35 weeks) and very preterm (28–29 weeks) babies,
Lage et al. [25] showed that guanodinoacetic acid (GAA,
the immediate precursor for creatine synthesis) concen-
trations in urine increased over the 35 (very preterm
group) or 14 postnatal days (preterm group) until dis-
charge, while urine creatine concentrations fell signifi-
cantly. These results were interpreted as indicating that
the accumulation of GAA was due to deficient hepatic
conversion to creatine, and potential creatine deficiency
was shown by the fall of urine creatine. Little is known
about intestinal transport of creatine in preterm or term
infants, but even if the baby was receiving nutrition by
mouth, neither breast milk or infant formula contain sig-
nificant amounts of creatine [26]. A further advantage of
creatine loading during pregnancy for the preterm infant
is that high levels of plasma creatine suppress the ex-
pression and activity of the enzyme arginine-glycine
aminotransferase (AGAT) in the kidney, which would
therefore have the effect of decreasing plasma levels of
GAA. High levels of GAA in blood are known to be
neurotoxic - the clinical manifestations of deficiency of
the hepatic enzyme guanidine acetate methyltransferase
(GAMT) and high circulating levels of GAA are intel-
lectual disability, extrapyramidal movement disorders,
and epilepsy [27,28].
There is a physiological cost of being born before the
major organ systems have developed sufficiently to meet
the demands of postnatal life; hence, the creatine status
of prematurely born infants needs close attention. For
human births before 34 weeks the heart, lung, kidney,
and brain are immature to the extent that respiratory
and cardiovascular support is often required, and resus-
citation procedures often place the brain at further risk
of hypoxic-ischemic injury [29,30]. Respiratory insuffi-
ciency also increases the demand on the neonatal dia-
phragm, a muscle that has not reached full functional
maturity in preterm infants and is prone to fatigue [31].
Renal function may also be limited, as shown by a re-
duced number of glomerular generations in the kidneys
of preterm infants [32]. Cardiovascular instability often
results in highly variable perfusion of the brain that, due
to immaturity of autoregulatory mechanisms, can result
in cerebral haemorrhage [33]. Even late preterm infants,
born 32–36 weeks gestation and who represent 80-85%
of all preterm births, are at risk of respiratory problems,
may require inotropic treatment, and suffer greater inci-
dences of cerebral palsy and cognitive impairments. For
infants born before 32 weeks, the incidence and severity
of these problems is worse [34].
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and should be the focus of further study. Some creatine
reference values reported for human infants (326 μmol/l)
and children (149 μmol/l) should be regarded as mislead-
ing because they were obtained from dried blood spots
and are thereby ‘contaminated’ by the high creatine con-
tent of red blood cells [35]. Total creatine content of the
brain (relative to all other metabolites, or calculated water
content, identified by magnetic resonance spectroscopy)
does not appear to change during in utero brain develop-
ment [36] or, if it does, by not more than 1.25-fold be-
tween 22 and 39 weeks gestation [37,38]. However, with
impaired brain development such as ventriculomegaly,
total creatine content appears to be raised [36], which
might be the consequence of sustained damage that leads
to white matter gliosis [39]. Nevertheless, it is clear that
acute hypoxic injury leads to depletion of ATP and
phosphocreatine in human infants and children [40,41],
confirming the animal studies and confirming that creat-
ine supplementation should be investigated as a therapy to
decrease the frequency and burden of hypoxic-ischaemic
brain damage at birth.
Creatine is a clinically important, safe nutritional
supplement
Increasing the cellular pool of creatine/phosphocreatine
through dietary creatine supplementation or subcutaneous
injections has been shown to be neuroprotective in several
animal models of neurodegenerative disorders and ac-
quired central nervous system injury [42]. Clinical trials
have shown that long-term creatine supplementation is
well tolerated, slowing the accumulation of glutamate in
the brain of early-onset Huntington’s Disease [43], without
serious side effects when given over years in patients with
Parkinson’s Disease [44], and improving short-term
and long-term outcomes for children recovering from
traumatic brain injury [45,46]. These neuroprotective
functions of creatine have recently been extended by
demonstrations that creatine improves cognitive function
in normal and elderly people [47,48], and improves cog-
nitive and motor skills in sleep-deprived subjects [49].
Consumption of creatine has also been shown to im-
prove glucose tolerance in healthy sedentary males [50],
and to improve muscle performance in elderly men and
post-menopausal women [51]. Based on its actions on
osteoblasts in vitro, creatine has been recommended as
a treatment for osteoporosis in women [52]. Thus, the
long-term use of creatine is being considered as a treat-
ment to alleviate health problems ranging from type-2
diabetes, metabolic syndrome, sarcopenia, osteopenia,
and cognitive decline.
Creatine, creatine monohydrate and creatine phosphate
are all currently unclassified by the relevant statutory
authorities in the EU (European Medicines Agency), UK(Medicine & Healthcare Products Regulatory Agency),
USA (Federal Drug Administration) and Australia (Thera-
peutic Goods Administration), and have no assigned cat-
egory for administration in pregnancy. In Australia, the
Complementary Medicines Evaluation Committee’s (CMEC)
most recent appraisal of creatine recommended that “there
is insufficient evidence, at this time, of adverse consequences
associated with the use of creatine and its salts to require
any restrictions on dosage”. While the long-term use of
creatine in adult humans has been considered in depth
and appears to be safe [53-57], caution should neverthe-
less be exercised in recommending its use in human preg-
nancy as we still await detailed studies. In human infants,
one study examined the oral administration of creatine to
treat apnoea of prematurity [58]. Although the 14 day cre-
atine treatment did not reduce the incidence of apnoea, it
was well tolerated by the premature infants with no side
effects noted.
The overwhelming evidence for considering creatine
supplementation to be safe was recently summarised by
Gualano et al. [57]. In our animal studies we have found
no evidence of changes to maternal physiology that
would raise concerns about recommending the use of
creatine in human pregnancy. Nevertheless, given that
pregnancy is normally associated with changes in fluid
balance in women, consideration should be given to de-
termining if creatine supplementation aggravates fluid
shifts during pregnancy. Creatine is an osmolyte, and in
very high concentrations could be associated with in-
creased water uptake by cells. In non-pregnant human
adults there has been some concern over possible dele-
terious effects of long-term, high-dose creatine supple-
mentation on kidney function [59], but this was not
confirmed by more recent work using 51Cr-EDTA clear-
ance in normal patients and those with type-2 diabetes
[60]. Studies measuring urine creatinine as a marker of
kidney function should be interpreted with caution given
that creatinine is the breakdown product of creatine and
creatine phosphate. Thus, the presence of high urine
creatinine would be expected during periods of high cre-
atine consumption, and is not necessarily indicative of
kidney damage [60].
Why creatine?
Understanding how supplemental creatine works to pre-
vent brain injury in the adult is useful in appreciating
how it might be applied to prevent or attenuate fetal and
neonatal brain injury. Many adult neuropathologies in
which creatine has been shown to be beneficial also en-
compass the primary mechanisms of injury induced by
hypoxia-ischemia (HI) in the immature brain, including
mitochondrial dysfunction, impaired energy metabolism,
excitotoxic injury and oxidative stress [42,61]. But it is
the prospect that supplementary creatine can act as a
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gives it a promise not provided by the current therapies;
e.g., magnesium sulphate or, in particular, head cooling.
The ‘pleiotrophic’ properties of creatine [62] arise from
the fact that in addition to acting as the essential spatio-
temporal metabolite by maintaining ATP via transfer of
the phosphoryl group to ADP, the creatine/phosphocrea-
tine (PCr) system has a number of other physiologically
important roles:
(i), acid–base balance: the rephosphorylation of ADP
utilizes a proton (PCr +Mg ADP +H+→ creatine +
MgATP), thus reducing the acidity of the intracellular
environment under hypoxic conditions [62,63]. This
may be important in maintaining muscle contractile
function [64,65]. However, while it has been thought
that the minimization of acid–base changes during
hypoxia in the presence of creatine were due only to
changes in cellular energy dynamics (i.e. donation of
proton with PCr), the study of Lawler et al. show that
creatine, when present at high concentrations in the
cell, and unlike PCr, has an inherent ability to scavenge
free radicals [66]. Thus the creatine/phosphocreatine
system has the ability to modulate changes of
intracellular acid–base balance that might arise during
periods of severe hypoxia in a direct, antioxidant
manner.
(ii), antioxidant actions: Perhaps related to this effect
on H + accumulation, creatine has been shown to be a
mild antioxidant in adult rat gastrocnemius in vitro
[66]. Furthermore, our results show the increased level
of malondialdehyde (product of lipid peroxidation)
caused by intrapartum hypoxia in spiny mouse pup
brain is completely prevented by maternal creatine
supplementation from mid-pregnancy [20]. Creatine
supplementation reduces the increase of 8-
hydroxydeoxyguanosine, a biomarker of oxidative
damage to DNA, which occurs as part of the natural
aging process [53,67]. Creatine has the property of
quenching superoxide, as opposed to increasing the
expression of antioxidant enzymes or attenuating ROS
production [68,69].
(iii), post-ischemic recovery of protein synthesis:
recovery of the decreased protein synthesis that
precedes neuronal cell loss in the post-ischemic brain is
faster after creatine pre-treatment in the oxygen-
glucose-deprived adult rat [70] and fetal guinea pig
hippocampal slices [71], resulting in a more favourable
histological outcome. In muscle, post-ischemic reactive
oxygen species (ROS) production has been shown to
disturb Ca2+ homeostasis and increase intracellular
Ca2+ levels resulting in a rise in protease activity, thus
increasing contractile protein degradation [72]. Creatine
has been shown to attenuate these effects by aiding inthe maintenance of ionic balance and by promoting
muscle protein synthesis.
(iv), improved cerebral vascular function: mice
pre-treated with creatine showed faster recovery of
cerebral blood flow during reperfusion after middle
cerebral artery occlusion, possibly due to greater dilator
responses to extra-luminal potassium and acidosis [73].
(v), interaction with the benzodiazepine receptor:
specific binding of creatine to the benzodiazepine
binding site of the GABAA receptor has been shown in
the chick brain [74], and animals fed a creatine
supplemented diet showed increased GABAergic
activity in some brain regions (striatum) [75]. The
anti-excitatory effect of increased GABAA receptor
activity is likely to be protective for the immature brain
(reviewed by [76]).
(vi), promoting the uptake of glutamate: uptake of
glutamate into synaptic vesicles is an ATP-dependent
process, thereby depending on creatine to maintain
ATP [77]. PCr has also been shown to promote the
uptake of glutamate into synaptic vesicles [78], and may
account for the neuroprotective capacity of creatine
against glutamate toxicity in neuronal cell culture [79].
(vii), stabilization of lipid membranes: PCr interacts
with phospholipid membranes to stabilize membranes
and prevent membrane permeabilisation [80].
Evidence that creatine protects against HIE at birth
Hypoxia-ischemia at birth occurs in approximately 4 per
1000 live term births [81], and depending on its severity
and duration 4-8% of these infants will die. Those in-
fants that do survive experience severe health problems,
stemming from irreversible multi-organ damage to the
brain, kidneys, heart and lungs [82]. The brain has re-
ceived the greatest attention with respect to hypoxia-
ischemia (HI) given that 20-70% of survivors have brain
damage with lifelong effects including mental and physical
disability, cerebral palsy and seizures [2,81]. However, the
recognition and treatment of other systemic complications
of HI, including acute kidney injury, muscle damage, and
compromise of heart function are essential for overall
homeostasis and thus survival.
Experimental studies in the precocial spiny mouse show
that a diet enriched with 5% creatine (approx. 1.36 g/kg
body mass/day) given from 0.5 gestation result in a 10-
30% increase in creatine content in fetal tissues (incl.
heart, kidney, liver, brain and muscle) and a 2-fold in-
crease in the placenta at term [83]. Fetal and maternal
liver creatine content was increased much more than in
muscle; similar findings of greatly increased hepatic
creatine after oral supplementation have been made in
non-pregnant animals [84]. The increased content of
creatine in the fetal liver at term may act as an add-
itional creatine pool available to the neonate that may
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tion. Importantly, the exposure to increased creatine
did not alter the protein expression of enzymes in the
neonatal kidney and liver - AGAT, GAMT respectively -
required for creatine synthesis postnatally [85]. Further-
more, this creatine treatment did not have any obvious
effects on maternal health status or body composition
(Ellery et al., unpublished data). These findings suggest
no harmful effects of the maternal creatine treatment
on the mother or neonate. While creatine supplementa-
tion had no effect on fetal weight in normal pregnancies,
effects where fetal growth restriction is present are yet to
be determined. Our studies showing the protective effects
of this creatine treatment on brain structure [20], postna-
tal behaviour [83], diaphragm [18], and kidney structure
and function [19] following asphyxial birth in the spiny
mouse gives reason to think that creatine may also benefit
the preterm infants in their premature transition from
fetal to newborn life.
Creatine and phosphocreatine (PCr) act by maintain-
ing intracellular ATP and thereby enable cells to prolong
mitochondrial function and resist the initial metabolic
collapse following HI [86]. Creatine may also target some
of the secondary responses to HI, including reducing oxi-
dative stress and promoting the post-ischemic recovery of
protein synthesis [71]. However, effective resistance to the
initial phase of a hypoxic challenge may prevent occur-
rence of the secondary wave of cell death altogether.
A limitation encountered in adult studies of the neuro-
protective properties of creatine is the slow transfer of
exogenous creatine into the brain, thought to be due to
the creatine transporter at the blood brain barrier work-
ing close to saturation, and leading to the view that
long-term, high dose creatine administration is required
to significantly increase the content of creatine in the
brain [87,88]. Indeed, early studies in mice [89], and
humans [16] appeared to show that pre-treatment with
creatine for several weeks to a month or more were re-
quired to raise brain creatine levels and to provide for
therapeutic benefits against cerebral ischaemia [89]. How-
ever, shorter supplement protocols have shown that creat-
ine levels in the brain can be increased. Lyoo et al. [90]
demonstrated significantly increased human brain creatine
levels using a supplementation protocol of 0.3 g/kg/day
for 7 days, followed by another seven days of 0.03 g/kg/
day. This result was consistent with Pan and Takahashi
[91] who reported significantly increased creatine con-
centrations in the human brain following creatine sup-
plementation at 20 g/day for 7 days. As for the longer
supplementation protocol described by Dechent et al.
[16], the studies using shorter supplement protocols used
1H-MRS and phosphorus magnetic resonance spectros-
copy (31P-MRS) to determine brain total creatine concen-
trations. Both techniques enabled the correlation of thechange in brain creatine with changes in high-energy
phosphate metabolism, and despite differences in the cre-
atine supplementation protocols and methods used to
measure creatine concentrations, significant increases in
brain creatine concentrations were observed in all cases.
However, creatine does appear to enter the immature
brain more readily, possibly because of higher expression
of the creatine transporter in endothelial cells of the
choroid plexus [92], allowing the developing brain to
utilize peripheral creatine more so than in the mature
brain (reviewed by [93]). In the postnatal rat brain, a sig-
nificant increase in the PCr/NTP (nucleoside triphos-
phate) ratio could be achieved by subcutaneous injections
of creatine at day 10, but not at day 20, and this also sig-
nificantly increased the recovery of cerebral PCr/NTP ra-
tio within 2 h post-hypoxia [86]. Creatine pre-treatment
also reduced brain oedema, and the incidence of severe
cystic cerebral infarction following hypoxic-ischaemia
in 7 day-old rats [71]. The creatine transporter is widely
expressed in the fetal rat brain, suggesting that the imma-
ture brain may have a greater capacity to take up creatine
from the circulation compared to the more mature brain,
although evidence also suggests that creatine may enter
the immature brain more easily by diffusion - i.e., a non-
carrier pathway [93]. Hence, it must be considered that
creatine supplementation given to pregnant women
even for only several weeks in late pregnancy is likely to
increase the resistance of the fetal brain to oxygen
deprivation or acidemic/hypercapnia at birth, or if poor
ventilatory efforts by the neonate require resuscitative
procedures immediately after birth.
What do we know of creatine metabolism in pregnancy?
Surprisingly little is known about the creatine status of
pregnant women, particularly that subset of women who
avoid meat and dairy products (vegetarians, vegans)
and therefore rely entirely on their own capacity to
synthesize creatine. In adult males, the creatine content
of muscles is ~30% lower in vegetarians compared to
those that eat meat, fish and dairy [94]. Notwithstanding
the greater exposure to phytoestrogens and the nearly 5
fold greater risk of hypospadias in boys [95], a vegetarian
or vegan diet does not appear to be associated with
increased obstetric problems or adverse pregnancy out-
comes, although this is usually discussed only in terms of
iron, vitamin B12 and total protein, and not creatine [96].
The possibility that the amount of creatine available for
transfer to the feto-placental unit is limited by this dietary
choice in pregnancy should be examined more closely.
In humans, and probably most omnivore species, cre-
atine is actively transported across the placenta; indeed
it appears to first accumulate in the placenta and then
diffuse down a concentration gradient into the fetal circu-
lation [97-99]. In animal studies, supplementary creatine
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increase in the placental creatine concentration [83]. In
the human placenta, the mRNA for the creatine trans-
porter (CrT) is detected early in pregnancy [100], and the
capacity for maternal-fetal transfer of creatine is present
from at least 13 weeks of gestation [101]. CrT protein ex-
pression is present in the syncytiotrophoblast of the term
human placenta (unpublished data), consistent with its
placement for uptake of creatine from the maternal circu-
lation, but the mechanism(s) for its release into the fetal
circulation is still a matter of conjecture. It has not yet
been satisfactorily established in any species if the placenta
expresses the creatine synthesising enzymes AGAT and
GAMTand is itself able to synthesise and release creatine.
As a metabolically active organ, it is likely that the pla-
centa itself has a creatine requirement - expression of sev-
eral creatine kinase isoforms, which are tightly coupled
with cellular energy requirements, has been shown to peak
in the term placenta [102]. Creatine kinase expression also
increases in the rat placenta during pregnancy, when its
decrease near to term is thought to signal placental senes-
cence [103], but whether this also occurs in the human
placenta is not known. The increase of placental creatine
kinase expression may follow from increased steroidogen-
esis, solute transport, and other placental activities such as
glucose-glycogen storage and amino acid metabolism,
which are all energy-driven processes that increase to-
wards term.
Observations on creatine kinase expression in fetal tis-
sues during the last trimester of pregnancy are under-
standably few, but on the assumption that increased
creatine kinase expression follows the need for increased
production of high-energy phosphates, it would not neces-
sarily follow that creatine kinase expression in fetal tissues
would match the changes that occur in the placenta. On
the other hand, they might, if indeed creatine kinase ex-
pression is modulated by oestrogen – and in particular,
ubiquitous mitochondrial [uMt] CK - as has been sug-
gested for placental creatine kinase [103]. Thus, total CK
and mitochondrial CK expression increased with gesta-
tional age in skeletal muscle samples obtained from pre-
term infants 28 to 36 weeks gestation [104], (although
these samples were obtained at post-mortem and at times
up to 6 days after birth, and confounding factors must in-
clude the babies condition leading to their early death and
postnatal muscle activity). Increased myocardial CK ex-
pression in late gestation fetal sheep can be explained by
increased demands on the heart with accelerating fetal
growth [105], but increased muscle ‘work’ would be a less
likely explanation for the increased CK expression in fetal
peripheral muscles.
In healthy women muscle creatine content increases from
[pre-pregnant] 200 mmol/kg alkali-soluble protein (ASP) to
223 mmol/ kg ASP at 18 weeks and 233 mmol/ kg ASP at36 weeks gestation [106]. This muscle creatine loading may
to be necessary to meet the uterine energy demands of
labour, which requires prolonged, recurrent episodes of very
intense uterine smooth muscle contractions [106]. The im-
pact of creatine supplementation on the pregnant uterus
bears consideration, but except for a small study on the ef-
fects of creatine on structure of the rat myometrium [106],
the involvement of creatine in myometrial activity, and the
increased activity associated with labour, has been little
studied. It has been suggested that decreased uterine con-
tractility following prolonged contractions might be pro-
tective in preventing hypoxic damage to the uterus - and
therefore, progressive fetal hypoxia [107]. However, this
physiological response to uterine ischemia might neverthe-
less have the consequence of causing progressive failure of
uterine ‘effort’ at term (i.e., uterine dystonia), a situation
that could be compensated for by creatine supplementa-
tion in late pregnancy.
Creatine synthesis in the fetus and newborn
While it is likely that the ‘dietary’ source of creatine for
the fetus is the maternal circulation, it is presently un-
clear when the capacity for creatine synthesis develops
in the fetus. Studies in the precocial spiny mouse suggest
that the reno-hepatic axis of creatine synthesis develops
late in gestation [108], and if this applies to human preg-
nancy would imply that infants born prematurely have
an under-developed capacity for creatine synthesis and
might therefore be at risk of becoming creatine deficient.
The dependence of the fetus on maternal creatine is sug-
gested by the fact that those rare infants born without
the capacity for creatine synthesis develop signs of
neurological dysfunction in the days and weeks after
birth [109,110] suggesting that they were not creatine
deficient before this, even though they are unable to pro-
duce creatine of their own. Important also for the neo-
nate is its capacity to reabsorb creatine from glomerular
filtrate. CrT protein is highly expressed in the proximal
tubule of the adult kidney and creatine excretion is very
low [111]. As discussed above, whether this is so for the
preterm infant is not yet fully known, and urinary creatine
loss may be important because preterm birth is often asso-
ciated with impaired renal function [112]. Urine compos-
ition has been used in the assessment of the risk of
developing HIE in neonates (e.g., urinary lactate/creatinine
ratio) [113], but the ability of the kidney to retain creatine
in preterm infants has not yet been examined.
Creatine, a multi-organ protectant against hypoxic injury
in the neonate
Our studies in the spiny mouse have shown that maternal
dietary creatine supplementation prevents hypoxic injury
to multiple organs including the brain [20], diaphragm
[18], limb skeletal muscle (unpublished data) and kidney
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and also improving postnatal growth [83]. Acute kidney
injury (AKI) and subsequent neonatal renal failure are
significant complications of HI; approximately 50% of
asphyxiated neonates present with some form of AKI, and
the severity of the condition strongly correlates with
subsequent morbidity, mortality, and poor neurological
outcomes [114]. The injury to the kidneys stems not
only from oxygen deprivation and ischemic tissue dam-
age, but also from the increased workload imposed on
the kidney to amend the changes to acid–base and elec-
trolyte levels which occur with the global insult of hyp-
oxia [115]. Our recent work on the kidney has shown
that the structural integrity of the kidney is significantly
impaired 24 h after birth hypoxia, with evidence of
shrunken glomeruli, dilated tubules, and impaired mi-
gration of the tubules into the medulla [19]. Supporting
our observation of tubular injury, the expression of neu-
trophil gelatinase-associated lipocalin (Ngal), a marker
of tubular injury, is significantly up-regulated after birth
hypoxia. These changes in kidney structure, and markers
of injury are completely prevented by maternal dietary
creatine supplementation.
Which obstetric population might benefit from creatine
supplementation?
The potential roles of creatine may be relevant to an
array of pregnancy conditions leading to preterm birth,
and therefore to high risk of HIE. One such condition is
preeclampsia, a common syndrome of pregnancy that
manifests after 20 weeks gestation with new-onset hyper-
tension alongside maternal end-organ dysfunction and/or
intrauterine fetal growth restriction [116], and is a factor
associated with nearly 50% of preterm births [117]. It
affects around 5% of all pregnancies [118], and is char-
acterized by significantly elevated levels of oxidative
stress within the maternal-fetal unit [119]. Gestational
diabetes mellitus is another common disease of human
pregnancy also affecting around 7% of women and
characterized by a state of increased oxidative stress
and increased risk of preterm birth [120,121]. These
pregnancy conditions along with many others warrant
investigation as to whether creatine may afford some
protective or therapeutic benefit.
In addition to pre-eclampsia, other obstetric conditions
that must be managed conservatively include cervical
incompetence, preterm premature rupture of the mem-
branes (PPROM), partial placental abruption and placenta
praevia, and fetal growth restriction. Fetal hypoxia, hypo-
glycaemia and activation of the fetal hypothalamic-adrenal
axis arise as consequences in many of these conditions,
leading not only to fetal growth restriction and preterm
delivery but also, potentially, to fetal death or stillbirth
[122,123]. Intrauterine demise of the fetus will alwaysinvolve mitochondrial energy failure. Therapeutic inter-
ventions that include bed rest [124], low dose aspirin
[125], or conventional nutrient supplementation [126]
have been shown to have limited success in reducing peri-
natal morbidity and mortality. Creatine supplementation
of the maternal diet is consistent with conservative man-
agement and would not interfere with the increased sur-
veillance of such high-risk patients that is now standard
clinical practice. The absence of any clinical trial at the
present time of creatine supplementation in human preg-
nancy is an obvious barrier to the implementation of this
treatment, although a trial of creatine for neuroprotection
of the human fetus at term has recently been proposed
[127]. Uterine smooth muscle contains remarkably low
levels of creatine, and ATP and phosphocreatine are read-
ily depleted by uterine activity [128]. Given that uterine
activity in late gestation can be uncoordinated and labour
sometimes ‘fail to progress’, a creatine supplementation
program in pregnant women might also decrease the
caesarean section rate.Conclusion
Creatine is considered a safe nutritional supplement for
adult humans and has been shown not only to increase
muscle mass and performance, prevent disease-induced
muscle atrophy and improve rehabilitation, but also to
strengthen cellular energetics in general [129]. By main-
taining tissue energy levels and preventing oxidative
stress, elevating tissue creatine levels by dietary supple-
mentation is able to prevent tissue injury induced by
hypoxia and circulatory collapse. In addition to yielding
ATP, the dephosphorylation of creatine utilizes free pro-
tons and ADP, thereby reducing the fall of intracellular
pH and aiding in the stabilization of the mitochondrial
membrane potential. Creatine may also have important
modulatory effects on the glutamate and GABA-A recep-
tor systems that raise the threshold for the onset of excito-
toxicity in the brain. The importance of creatine may
extend beyond protecting the brain to preventing damage
to other organs. In pregnancy, hypoxia, inflammation, and
oxidative stress are reasonably common events that lead
to compromise of not only the brain, but other important
organ systems, rendering them particularly vulnerable to
hypoxic-ischemic damage that can occur at birth, particu-
larly preterm birth. The use of creatine in human preg-
nancy and neonatal practice should therefore be evaluated
as a possible prophylactic therapy in its own right, or as
an adjunct to conventional treatments such as magnesium
sulphate when preterm labour is likely, or in HIE when
hypothermia is used.
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